Healthlynked Corp (HLYK)

$3.50 0.00 (N/A)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 1,300
Avg Vol 1,904
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 100%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

HealthLynked Corp., a healthcare technology company, operates a cloud-based patient information network and record archiving system in the United States. It operates through three segments: Digital Healthcare, Medical Distribution, and Health Services. The company's Digital Healthcare segment develops, operates, and manages HealthLynked Network, an online personal medical information and record archive system that facilitates efficient management of medical records and care, allows seamless pati...

Industry: Medical Care Facilities
Sector: Healthcare
Phone: 800 928 7144
Address:
1265 Creekside Parkway, Suite 200, Naples, United States
GordoHLYK13
GordoHLYK13 Jun. 13 at 2:18 PM
$HLYK $NEO $AMZN Been holding $HLYK since 2019. Started with over 800k shares pre-split under $.05 — now sitting around 8k shares with a much higher average near $5.50 after the reverse split. Yeah, the dilution and cash concerns are real, but I’m still holding because this isn’t just a tiny clinic company anymore. HLYK is building a healthcare AI/data ecosystem with telemedicine, patient integration, ARi AI, and expanding partnerships. The market only sees the struggles. I see a micro-cap trying to evolve into a scalable digital healthcare platform. If management secures funding and finally monetizes the tech, the upside from these levels could be enormous due to the tiny market cap. High risk, yes — that’s why I’m here Despite the dilution, reverse split, and survival concerns, the article confirms $HLYK is still fighting to transform itself into an AI-driven digital healthcare platform — and if they execute, the upside from these beaten-down levels could be enormous.
0 · Reply
NVDAMillionaire
NVDAMillionaire Jun. 9 at 5:41 PM
$HLYK Excellent article that nails exactly where HLYK stands right now. So if you want to update your HLYK knowledge or get acquainted with HLYK, this is a must read. https://everyticker.com/quote/HLYK/analysis/healthlynked-s-digital-hail-mary-a-micro-cap-s-race-against-time-and-capital-otc-hlyk
0 · Reply
Lambrusco
Lambrusco Jun. 5 at 3:51 PM
$HLYK Gordo, my previous responses dont seem to be appearing. Yes, I have noticed the recent increase in shareprice. Here is what investors (esp those with relatively large number of shares) should be aware of: The daily VOLUME is usually quite low (a few thousand at best and sometimes less than that). The BID is usually MUCH lower than the actual shareprice (as I type this it is $1.X LESS than the current shareprice). And the block required is usually MANY times the daily volume (yesterday it was 30K and today it is over 100K). So, even if you wanted to sell only 1000 shares, you would need a collective number of buyers of many MORE thousands. A sell order would usually hang for days/weeks and/or reduce in value to complete. I dont mention this to be a "basher"; I have experienced this before with similar OTC stocks. Your excitement of the "rise" in shareprice should be tempered, imo.
0 · Reply
GordoHLYK13
GordoHLYK13 Jun. 4 at 3:24 PM
$HLYK thank you HealthLynked team
2 · Reply
GordoHLYK13
GordoHLYK13 Jun. 3 at 9:46 PM
$HLYK @Lambrusco Calling it “not an AI play” misses the point. Nobody is saying HLYK is an OpenAI-level AI company—it’s about AI-enabled workflow layered into a healthcare turnaround with a low-float setup. High risk, sure. But that’s exactly where fast repricing comes from if execution even starts to stick. And you don’t know me or Uncle Dent
1 · Reply
GordoHLYK13
GordoHLYK13 Jun. 2 at 8:56 AM
$HLYK Bull case for HealthLynked: Tiny float, tiny market cap, huge healthcare AI angle. HealthLynked is shifting toward a cloud-based healthcare network focused on connecting patients, doctors, and medical data while incorporating AI tools. The company has also highlighted plans around digital healthcare expansion and a potential Nasdaq uplisting, which could put it on more investors’ radar if executed successfully. Bullish punch: HLYK is the definition of a high-risk, high-reward lottery ticket — a micro-cap healthcare AI play with a tiny share count, digital health ambitions, and Nasdaq aspirations. If management executes and gains traction, it wouldn’t take much buying pressure to send this thing moving fast. 🚀
1 · Reply
GordoHLYK13
GordoHLYK13 May. 1 at 9:07 PM
$GNS $HLYK $STUB $NEO Good luck everyone in your investments. These are mine with my fun money, separate from my Nationwide Pro account and FRS pension. $GNS 10k shares average $.2741 * Arbitration win: 7.4M shares returned + $8M cash * 2026 outlook: $20–$22M revenue, potential positive adjusted EBITDA * AI education expansion + “Space Capsule” rollout $STUB (StubHub) 3k shares average $6.25 * Q1 2026 earnings scheduled for May 13, 2026 (after close) * Expanding globally in Asia and Latin America $NEO (NeoGenomics) 3k shares $7.97 * Raised 2026 revenue guidance to ~$797–$803M * New cancer test (RaDaR ST MRD) targeting large market * New insurance coverage boosting demand $HLYK (HealthLynked) 8k shares $5.54 * Working toward NASDAQ listing via $7M offering * Launching AI healthcare assistant (ARi) for patient management Just sharing what I’m personally positioned in—nothing more.
0 · Reply
GordoHLYK13
GordoHLYK13 Apr. 17 at 11:20 AM
$HLYK NASDAQ uplisting is the main rocket here. They already filed a $7M offering targeting a NASDAQ move, and recent proxy filings suggest key approvals are coming. Stock already running shows the market is front-running bigger exchange exposure and new buyers. $DCGO DocGo officially exploring strategic alternatives is Wall Street code for buyout, merger, or major deal. Add raised 2026 revenue guidance and improving margins, and this looks like a cheap healthcare asset getting noticed. If they clear $1 compliance, momentum can hit fast. $STUB StubHub looks beaten down but loaded with upside. FTC settlement clears a major cloud, analysts see huge undervaluation, and profitability is expected this year. The Live Nation monopoly lawsuit could open more market share for rivals like StubHub, giving them a cleaner lane to grow and compete. That’s my portfolio—three asymmetric plays with catalysts, where patience and positioning now could turn into serious money later.
1 · Reply
GordoHLYK13
GordoHLYK13 Mar. 27 at 2:45 PM
$HYLN My two biggest plays $HYLN and $HLYK 🔥 $HYLN got that Karno power, Navy testing it, ABM backing — real momentum building. $HLYK steady, strong fundamentals, and just started processing to Nasdaq too — long-term grind while others sleep. Enjoying the Naples beach Have a great weekend
0 · Reply
GordoHLYK13
GordoHLYK13 Feb. 21 at 7:07 PM
$NEO $HLYK 2026 Together We Fly https://youtu.be/ztJVbDCifO8?si=1jToNIeu3ri5AA4u
0 · Reply
Latest News on HLYK
No data available.
GordoHLYK13
GordoHLYK13 Jun. 13 at 2:18 PM
$HLYK $NEO $AMZN Been holding $HLYK since 2019. Started with over 800k shares pre-split under $.05 — now sitting around 8k shares with a much higher average near $5.50 after the reverse split. Yeah, the dilution and cash concerns are real, but I’m still holding because this isn’t just a tiny clinic company anymore. HLYK is building a healthcare AI/data ecosystem with telemedicine, patient integration, ARi AI, and expanding partnerships. The market only sees the struggles. I see a micro-cap trying to evolve into a scalable digital healthcare platform. If management secures funding and finally monetizes the tech, the upside from these levels could be enormous due to the tiny market cap. High risk, yes — that’s why I’m here Despite the dilution, reverse split, and survival concerns, the article confirms $HLYK is still fighting to transform itself into an AI-driven digital healthcare platform — and if they execute, the upside from these beaten-down levels could be enormous.
0 · Reply
NVDAMillionaire
NVDAMillionaire Jun. 9 at 5:41 PM
$HLYK Excellent article that nails exactly where HLYK stands right now. So if you want to update your HLYK knowledge or get acquainted with HLYK, this is a must read. https://everyticker.com/quote/HLYK/analysis/healthlynked-s-digital-hail-mary-a-micro-cap-s-race-against-time-and-capital-otc-hlyk
0 · Reply
Lambrusco
Lambrusco Jun. 5 at 3:51 PM
$HLYK Gordo, my previous responses dont seem to be appearing. Yes, I have noticed the recent increase in shareprice. Here is what investors (esp those with relatively large number of shares) should be aware of: The daily VOLUME is usually quite low (a few thousand at best and sometimes less than that). The BID is usually MUCH lower than the actual shareprice (as I type this it is $1.X LESS than the current shareprice). And the block required is usually MANY times the daily volume (yesterday it was 30K and today it is over 100K). So, even if you wanted to sell only 1000 shares, you would need a collective number of buyers of many MORE thousands. A sell order would usually hang for days/weeks and/or reduce in value to complete. I dont mention this to be a "basher"; I have experienced this before with similar OTC stocks. Your excitement of the "rise" in shareprice should be tempered, imo.
0 · Reply
GordoHLYK13
GordoHLYK13 Jun. 4 at 3:24 PM
$HLYK thank you HealthLynked team
2 · Reply
GordoHLYK13
GordoHLYK13 Jun. 3 at 9:46 PM
$HLYK @Lambrusco Calling it “not an AI play” misses the point. Nobody is saying HLYK is an OpenAI-level AI company—it’s about AI-enabled workflow layered into a healthcare turnaround with a low-float setup. High risk, sure. But that’s exactly where fast repricing comes from if execution even starts to stick. And you don’t know me or Uncle Dent
1 · Reply
GordoHLYK13
GordoHLYK13 Jun. 2 at 8:56 AM
$HLYK Bull case for HealthLynked: Tiny float, tiny market cap, huge healthcare AI angle. HealthLynked is shifting toward a cloud-based healthcare network focused on connecting patients, doctors, and medical data while incorporating AI tools. The company has also highlighted plans around digital healthcare expansion and a potential Nasdaq uplisting, which could put it on more investors’ radar if executed successfully. Bullish punch: HLYK is the definition of a high-risk, high-reward lottery ticket — a micro-cap healthcare AI play with a tiny share count, digital health ambitions, and Nasdaq aspirations. If management executes and gains traction, it wouldn’t take much buying pressure to send this thing moving fast. 🚀
1 · Reply
GordoHLYK13
GordoHLYK13 May. 1 at 9:07 PM
$GNS $HLYK $STUB $NEO Good luck everyone in your investments. These are mine with my fun money, separate from my Nationwide Pro account and FRS pension. $GNS 10k shares average $.2741 * Arbitration win: 7.4M shares returned + $8M cash * 2026 outlook: $20–$22M revenue, potential positive adjusted EBITDA * AI education expansion + “Space Capsule” rollout $STUB (StubHub) 3k shares average $6.25 * Q1 2026 earnings scheduled for May 13, 2026 (after close) * Expanding globally in Asia and Latin America $NEO (NeoGenomics) 3k shares $7.97 * Raised 2026 revenue guidance to ~$797–$803M * New cancer test (RaDaR ST MRD) targeting large market * New insurance coverage boosting demand $HLYK (HealthLynked) 8k shares $5.54 * Working toward NASDAQ listing via $7M offering * Launching AI healthcare assistant (ARi) for patient management Just sharing what I’m personally positioned in—nothing more.
0 · Reply
GordoHLYK13
GordoHLYK13 Apr. 17 at 11:20 AM
$HLYK NASDAQ uplisting is the main rocket here. They already filed a $7M offering targeting a NASDAQ move, and recent proxy filings suggest key approvals are coming. Stock already running shows the market is front-running bigger exchange exposure and new buyers. $DCGO DocGo officially exploring strategic alternatives is Wall Street code for buyout, merger, or major deal. Add raised 2026 revenue guidance and improving margins, and this looks like a cheap healthcare asset getting noticed. If they clear $1 compliance, momentum can hit fast. $STUB StubHub looks beaten down but loaded with upside. FTC settlement clears a major cloud, analysts see huge undervaluation, and profitability is expected this year. The Live Nation monopoly lawsuit could open more market share for rivals like StubHub, giving them a cleaner lane to grow and compete. That’s my portfolio—three asymmetric plays with catalysts, where patience and positioning now could turn into serious money later.
1 · Reply
GordoHLYK13
GordoHLYK13 Mar. 27 at 2:45 PM
$HYLN My two biggest plays $HYLN and $HLYK 🔥 $HYLN got that Karno power, Navy testing it, ABM backing — real momentum building. $HLYK steady, strong fundamentals, and just started processing to Nasdaq too — long-term grind while others sleep. Enjoying the Naples beach Have a great weekend
0 · Reply
GordoHLYK13
GordoHLYK13 Feb. 21 at 7:07 PM
$NEO $HLYK 2026 Together We Fly https://youtu.be/ztJVbDCifO8?si=1jToNIeu3ri5AA4u
0 · Reply
GordoHLYK13
GordoHLYK13 Feb. 21 at 1:27 PM
$HLYK HealthLynked (HLYK): Top 6 Catalysts 1. Nasdaq S-1 Filed: Official application for uplisting is active (targeting $4.00–$6.00 range). 2. Nasdaq Debut: Moving from OTC to the "Big Board" opens the door to institutional and retail millions. 3. Insider Confidence: Dr. Dent consolidated $5.7M in debt into a note convertible at $4.25 per share. 4. Payer Pilot: New partnership with PBACO to launch an AI pilot program with UnitedHealthcare. 5. ARi AI Rollout: "National Initiative" launched to integrate the AI assistant with pharma and research giants. 6. Low Float Physics: Only 1.9M shares available; any major news could trigger a "vertical" price squeeze. $NEO
0 · Reply
GordoHLYK13
GordoHLYK13 Feb. 21 at 1:26 PM
$NEO NeoGenomics (NEO): Top 7 Catalysts 1. RaDaR ST Launch: Full U.S. clinical rollout of the "next-gen" cancer test is starting this month (Feb 2026). 2. Lee Health Lab: NEO’s partnership anchored in Lee Health’s new $150M molecular lab expansion. 3. The "Beat & Raise": Q1 earnings (May 2026) likely to smash the "conservative" 2026 guidance. 4. NGS Growth: Revenue for high-profit sequencing is surging at 23% year-over-year. 5. Sales Force Blitz: Expanding to 165 oncology specialists this year to drive massive test volume. 6. Reimbursement Win: MolDx/Medicare pricing for new liquid biopsies is locked in for 2026. 7. Buyout Potential: Dominant Florida footprint makes NEO a prime acquisition target for Quest or LabCorp. $HLYK
0 · Reply
GordoHLYK13
GordoHLYK13 Feb. 21 at 12:55 PM
$HLYK Nasdaq S-1 Filed! Dr. Dent Betting Big! The transformation is real. Dr. Dent (founder of $NEO repeating the playbook. 🩺 The News: HealthLynked just filed its S-1 for Nasdaq uplisting with a target range of $4.00–$6.00. The TCOB Checklist: • Founder Confidence: Dr. Dent just consolidated $5.7M in debt into a note convertible at $4.25. He isn't just the CEO; he's the biggest bull. • Commercial Scalability: ARI AI platform is moving into payer/employer channels (high-margin recurring revenue). • Nasdaq Ready: Cleanup of governance and reporting is done. • Local Synergy: Strategic positioning with Southwest FL medical heavyweights (Millennium, Lee Health, NCH).
0 · Reply
GordoHLYK13
GordoHLYK13 Feb. 21 at 12:54 PM
$NEO While Others Panic! Don't let the post-earnings shakeout fool you. 📊 Dig Deep: NEO just beat Q4 Rev & EPS, hitting its 10th straight quarter of positive Adj. EBITDA. Volume spike at $9.89 + RSI at 26 = classic "capitulation" bottom. Why I’m Bullish: • Institutional Support: Zacks #2 (Buy) upgrade just hit. • Insiders are IN: COO Warren Stone’s recent Form 4 shows he’s holding 120k+ shares and huge options at $13-$19. He only sold a fraction for taxes. • Local Moat: Deeply integrated with Lee Health's new $150M lab expansion and NCH oncology. • RaDaR ST: Full clinical launch this month. The "dishes are done." Accumulating here. 🚀 #Oncology #FortMyers #Value Watch out $NTRA $HLYK CEO Dent $NEO founder
0 · Reply
GordoHLYK13
GordoHLYK13 Feb. 8 at 5:46 PM
$HLYK The $HYLK Bullish Punch CEO Dr. Michael Dent is going "All-In." This filing is a massive signal of insider confidence for three key reasons: • The Ultimate Buy-In: The CEO converted $5.7M of personal advances and unpaid salary into a secured note. He’s not walking away; he’s doubling down on the company’s survival and success. • High Expectations: The conversion price is set at $4.25 per share. By locking in this price, the CEO is signaling he believes the stock is worth significantly more than its current trading level. • Balance Sheet Cleanup: He’s rolled "messy" short-term debt and old liabilities into one 3-year note, giving the company a clear runway until 2029 to execute its growth plan. The Bottom Line: The captain isn't just staying with the ship; he’s buying a bigger stake at a premium. Sec filing firm 8k released on Friday after market closed This week is bullish $TDOC $NEO
1 · Reply
GordoHLYK13
GordoHLYK13 Jan. 27 at 2:02 PM
$HLYK Calm before the storm — NASDAQ: HLYK is quietly building leverage as its patient-centric healthcare network and data-driven platform connects providers, patients, and medical data into one ecosystem, positioning the company for scalable growth, monetization, and broader adoption while the market still sleeps.
0 · Reply
wheresdannynow
wheresdannynow Jan. 26 at 6:22 PM
BIOTECH MOVERS 🟢 TOP GAINERS: 1. $MHUAF +32.8% 2. $GTHP +30.0% 3. $CHRS +29.6% 🔴 TOP LOSERS: 1. $SONN -59.4% 2. $MHUA -45.7% 3. $HLYK -31.8%
0 · Reply
TheShredder
TheShredder Jan. 23 at 8:52 PM
$HLYK if they don’t stay above 4 they have to try again…not hard to see what they are doing here but u need some sort of news to get people to buy coming out of the reverse split otherwise you get exposed…Mr. Dent is trying to take the shortcut. Show us a reason to buy and u will get your uplist
0 · Reply
BioBum
BioBum Jan. 23 at 1:10 PM
$HLYK No liquidity
0 · Reply
GordoHLYK13
GordoHLYK13 Jan. 22 at 5:45 PM
$HLYK Most people see a "healthcare company," but the market is starting to price in a Global AI Health Network. ✅ The Momentum: 10 days of straight green. From $1.50 to $6.00+ in three weeks. 📈 ✅ The Big Move: Nasdaq uplisting application is IN. Moving from OTC to the Big Board in H1 2026 ✅ The Tech: Over 1 Million members integrated into their patented ARi AI ecosystem. 🤖🏥 ✅ The Team: New heavy-hitter COO and insurance experts added to the board. The gap is closing. Don't say you weren't watching. #HLYK #Nasdaq #AI #HealthTech HealthLynked is bridging the gap between legacy healthcare and AI-driven medicine. They have the tech, they have the data, and now they have the momentum to hit the Big Board #arthrex
0 · Reply
Conquistador69
Conquistador69 Jan. 22 at 5:04 PM
$HLYK IM PRAYING THIS HOLDS NOW
0 · Reply
GordoHLYK13
GordoHLYK13 Jan. 22 at 3:03 PM
My two diamonds $HLYK and $HYLN
1 · Reply